ArticleAsian Pacific journal of cancer prevention : APJCP2025
The Genetic Influence of Programmed Death Ligand-1 (PD-L1) Single Nucleotide Polymorphisms on the Incidence of B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PD-L1/Cancers · 2026Article
- Functional genetic variants in immune-checkpoint molecules and susceptibility to Nasopharyngeal carcinoma in a Tunisian case-control study.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was conducted to investigate the relationship between rs4143815 (C>G) and rs2890658 (A>C) of the PD-L1 (Programmed Death-Ligand 1) gene and the risk of developing non-Hodgkin's lymphoma (B-NHL) in a cohort of Egyptian population.
methodsIn this case-control study, which included one hundred patients (males and females) diagnosed with B-NHL from Kasr El Aini hematology clinic, their age ranged between 18 and 71 years and 100 age and sex matched healthy controls from outpatient clinic. Three ml venous blood was withdrawn from all subjects and collected in EDTA vacutainer® and kept frozen at -20˚C till time of DNA extraction. DNA samples were extracted from blood samples using GeneJETTM Genomic DNA Purification Kit from Thermo Fisher. Genotyping was determined using Custom TaqMan® SNP Genotyping Assays from Applied biosystems by real-time PCR, and subsequently extensive statistical analysis was performed to investigate the clinical value of these polymorphisms. Patients' clinical information was obtained from patient's medical records.
resultsThe obtained results of the current study demonstrated GG genotype of PD-L1 rs4143815 and the CC genotype of PD-L1 rs2890658 were observed to be more prevalent among NHL patients compared to those reported for the healthy controls (62%, 80% vs 58%, 77%), respectively, however these results revealed no significant association between the studied SNPs of PDL1 gene and risk of NHL (p=0.837, *). Regarding survival analysis, results of 36 and 60 months DFS for the common genotype (GG) of rs4143815 versus the combined genotype (GC & CC) were (67%, 44.6% vs 63.8%, 63.8%), respectively (p=0.249) as well as results of 36, 60 months DFS for the common genotype (CC) of rs2890658 versus the combined genotype (AA & AC) revealed (61.5%, 46.1% vs 83.3%, 83.3%), respectively which was statistically insignificant (p=0.599), therefore PDL1 rs4143815 & rs2890658 polymorphisms have no significant impact on patients' DFS.
conclusionsOur findings provided the first evidence that PD-L1 rs4143815 (C>G) and rs2890658 (A>C) are not molecular susceptibility markers for B-NHL in Egyptians, at least in the studied population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.